
Oragenics, Inc.
- Jurisdiction
United States - LEI
549300639MGD19K4ZW90 - ISIN
US6840235005 (OGEN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Read full profile
Fundamentals
- Net revenue
€2.68M - Gross margin
0.0% - EBIT
-€8.13M - EBIT margin
-303.6% - Net income
-€8.79M - Net margin
-328.1%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions